{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:08:50Z","timestamp":1790662130553,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.ymgme.2006.09.003","type":"journal-article","created":{"date-parts":[[2006,11,2]],"date-time":"2006-11-02T16:40:16Z","timestamp":1162485616000},"page":"157-163","source":"Crossref","is-referenced-by-count":100,"title":["The long-term international safety experience of imiglucerase therapy for Gaucher disease"],"prefix":"10.1016","volume":"90","author":[{"given":"Kathryn","family":"Starzyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske","family":"Kingma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2006.09.003_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0021-9258(18)97611-8","article-title":"The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue","volume":"240","author":"Brady","year":"1965","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2006.09.003_bib2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2006.09.003_bib3","unstructured":"W. Kingma, E. Chadbourne, R. Cintron, S. Richards, G.C. Cox, Safety and immunogenicity of recombinant enzyme replacement therapy for lysosomal storage disorders, Am. Soc. Hum. Genet. Annual Meeting."},{"key":"10.1016\/j.ymgme.2006.09.003_bib4","unstructured":"Cerezyme Package Insert, Genzyme Corporation, April 2005."},{"key":"10.1016\/j.ymgme.2006.09.003_bib5","unstructured":"K. Starzyk, W. Kingma, Long term international safety monitoring of enzyme replacement therapy in Gaucher disease, Am. Soc. Hum. Genet. Meeting 2003."},{"key":"10.1016\/j.ymgme.2006.09.003_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2006.09.003_bib7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood.V82.5.1402.1402","article-title":"Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase","volume":"82","author":"Richards","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2006.09.003_bib8","first-page":"79","article-title":"Gaucher disease: an overview of clinical characteristics and therapy","volume":"19","author":"Kingma","year":"1996","journal-title":"J. Intraven. Nurs."},{"key":"10.1016\/j.ymgme.2006.09.003_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jcem-38-1-14","article-title":"Collaborative study of the effects of human growth hormone in growth hormone deficiency. II. Development and significance of antibodies to human growth hormone during the first year of therapy","volume":"38","author":"Frasier","year":"1974","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2006.09.003_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0031-3955(16)34614-4","article-title":"Allergy to insulin","volume":"31","author":"Ross","year":"1984","journal-title":"Pediatr. Clin. North Am."},{"key":"10.1016\/j.ymgme.2006.09.003_bib11","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1200\/JCO.1988.6.10.1604","article-title":"Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation","volume":"6","author":"Figlin","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymgme.2006.09.003_bib12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/infdis\/169.4.875","article-title":"Interferon (IFN)-alpha 2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN-alpha 2a therapy","volume":"169","author":"Crowe","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymgme.2006.09.003_bib13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymgme.2006.09.003_bib14","first-page":"1","article-title":"Overview of inhibitors to factor VIII and IX","volume":"150","author":"Roberts","year":"1984","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.ymgme.2006.09.003_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/jir.1993.13.333","article-title":"Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up","volume":"13","author":"Knobler","year":"1993","journal-title":"J. Interferon. Res."},{"key":"10.1016\/j.ymgme.2006.09.003_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00915254","article-title":"The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)","volume":"6","author":"Allegretta","year":"1986","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ymgme.2006.09.003_bib17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/ndt\/gfg164","article-title":"Immunogenicity of therapeutic proteins","volume":"18","author":"Schellekens","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2006.09.003_bib18","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood-2005-02-0508","article-title":"Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"106","author":"Bennett","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2006.09.003_bib19","series-title":"Biopharmaceutical Products in the US and European Markets","author":"Rader","year":"2005"},{"key":"10.1016\/j.ymgme.2006.09.003_bib20","unstructured":"F.J. Grogan, R.E. Pearson, C. Connor (Eds.), in: Mosby\u2019s Drug Consult 2006 February Update, Mosby, Inc, Missouri."},{"key":"10.1016\/j.ymgme.2006.09.003_bib21","unstructured":"Approved Biotechnology Drugs. BIO. January 20, 2006. Available from: <http:\/\/www.bio.org\/speeches\/pubs\/er\/approveddrugs.asp\/>."},{"key":"10.1016\/j.ymgme.2006.09.003_bib22","unstructured":"Therapeutic Biological Products Approvals. Updated: December 12, 2003. FDA. February 20, 2006. Available from: <http:\/\/www.fda.gov\/cder\/biologics\/biologics_table.htm\/>."},{"key":"10.1016\/j.ymgme.2006.09.003_bib23","unstructured":"Drugs @ FDA. August 2, 2006. Available from: <http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm\/>."},{"key":"10.1016\/j.ymgme.2006.09.003_bib24","unstructured":"List of Authorized Products (EPARS). EMEA. February 21, 2006. Available from: <www.emea.europa.eu\/index\/indexh1.htm\/>."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206002976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719206002976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T06:38:24Z","timestamp":1628059104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719206002976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S1096719206002976"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2006.09.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}